Annals of Oncology 14:894-897, 2003
© 2003 European Society for Medical Oncology
Original Paper |
CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma
1 Department of Medicine, Division of Oncology and 2 Department of Internal Medicine, University of North Dakota School of Medicine; 3 Department of Medicine and 4 Department of Pathology, Meritcare Health System, Fargo, ND; 5 Department of Pathology, IMPATH Laboratories, Los Angeles, CA, USA
Received 28 October 2002; revised 9 January 2002; accepted 18 February 2003
Background:
The aim of this study was to determine the incidence and role of CD117 (c-KIT) overexpression as a predictive/prognostic marker in extensive-stage small-cell lung carcinoma (ESSCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of ESSCLC.
Patients and methods:
A chart review for demographic and clinical data was performed on patients with ESSCLC diagnosed between 1991 and 2001. CD117 overexpression was evaluated using immunohistochemistry (A4052 polyclonal antibody) performed on archival paraffin-embedded specimens.
Results:
Two hundred and twenty-three patients with ESSCLC were identified, of whom 193 (84 females, 109 males) with a mean age of 68.5 years (range 42–90) had adequate tissue specimens available for CD117 testing. The most commonly presenting symptom was weight loss, seen in 61 patients (31.6%). Of the 193 specimens, 54 (27.9%) showed CD117 overexpression. The median length of survival for CD117-positive patients was 9 months as compared with the CD117-negative population, in whom the survival was 6 months (P = 0.025, Cox proportional hazard method).
Conclusions:
CD117 overexpression detected using immunohistochemistry is observed in about a third of patients with ESSCLC and does not have statistically significant prognostic value. However, CD117 may be a potential target for site-specific immunotherapy in ESSCLC. Our findings suggest a role for clinical trials assessing the role of selective tyrosine kinase inhibitor STI-571 (alone or in combination with conventional therapy) in patients with ESSCLC.
Key words: c-kit, extensive stage, small-cell lung carcinoma, survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Rehfeld, H. Geddert, A. Atamna, H. E. Gabbert, U. Steidl, R. Fenk, R. Kronenwett, R. Haas, and U.-P. Rohr Coexpression of Fragile Histidine Triad and c-kit Is Relevant for Prediction of Survival in Patients with Small Cell Lung Cancer. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2232 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Meuwissen and A. Berns Mouse models for human lung cancer Genes & Dev., March 15, 2005; 19(6): 643 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Raspollini, G. Amunni, A. Villanucci, G. Baroni, A. Taddei, and G. L. Taddei c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study Ann. Onc., April 1, 2004; 15(4): 594 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Heinrich Is KIT an Important Therapeutic Target in Small Cell Lung Cancer?: Commentary re: B. E. Johnson et al., Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin. Cancer Res., 9: 5880-5887, 2003. Clin. Cancer Res., December 1, 2003; 9(16): 5825 - 5828. [Full Text] [PDF]
|
|